.Merck trumps incomes assumptions, increases purchases expectation on solid requirement for leading medicines like Keytruda CNBCMerck & Co. (MRK US) Beats Earnings Estimates as Keytruda Sales Surge BloombergMerck Supply: Pharma Titan Posts Sturdy End Results, But Expectation Falls Short Investor's Company DailyMerck Announces Second-Quarter 2024 Financial Outcomes Yahoo FinanceMerck trumps earnings and sales requirements surrounded by Keytruda asset, but provides mixed full-year outlook MarketWatch.